For the quarter ending 2026-03-31, GRI had $2,819K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Change in fair value of warrant liability | - | 0 | 0 | 0 |
| Net loss | -1,998 | -2,659 | -3,359 | -5,938 |
| Depreciation expense | 1 | 1 | 1 | 2 |
| Stock-based compensation expense | 31 | 67 | 465 | 261 |
| Change in operating lease right-of-use assets | 13 | 12 | 13 | 23 |
| Prepaid expenses and other current assets | -105 | 14 | -132 | -133 |
| Accounts payable | -1,507 | 272 | 20 | 371 |
| Accrued expenses | -317 | -638 | 428 | 269 |
| Operating lease liabilities | -13 | -12 | -13 | -23 |
| Cash used in operating activities | -3,685 | -2,971 | -2,313 | -4,902 |
| Purchase of property and equipment | - | 3 | - | - |
| Cash used in investing activities | - | -3 | - | - |
| Proceeds from issuance of common stock in financing transaction / under atm facility-Through Financing | - | 8,000 | 0 | 5,000 |
| Proceeds from issuance of common stock in financing transaction / under atm facility-At The Market Offering | - | 0 | 1,619 | 941 |
| Proceeds from warrant exercise | - | 0 | 0 | - |
| Proceeds from issuance of common stock under atm facility | 6,819 | - | - | - |
| Payment for fractional shares in connection with reverse stock split | 1 | 0 | 0 | 1 |
| Payment of stock issuance costs | 314 | 852 | 373 | 944 |
| Cash provided by (used in) financing activities | 6,504 | 7,148 | 1,246 | 4,996 |
| Net increase (decrease) in cash and cash equivalents | 2,819 | 4,174 | -1,067 | 94 |
| Cash and cash equivalents at beginning of period | 8,229 | 4,055 | 5,028 | - |
| Cash and cash equivalents at end of period | 11,048 | 8,229 | 4,055 | - |
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)